Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes
Diabetic Medicine · 05.11.2026
DOI: 10.1111/dme.70495 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetic Medicine, online erschienen am 05.11.2026. Verfasst von Maja Witowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Faculty of Engineering, Imperial College London, London, UK. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Leona M. and Harry B. Helmsley Charitable Trust, Diabetes UK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Type 1 diabetes (T1D) is a self‐driving autoimmune condition leading to the death of insulin‐producing β‐cells of the pancreas. β‐cell‐reactive immune cell extravasation into the intra‐islet space is fuelled by a cycle of inflammation including immune, vascular and endocrine dysfunction. Since clinical pancreatic biopsy is contraindicated, T1D research relies on static in vitro culture or in vivo models that either cannot fully replicate the dynamic interactions between the three different tissue types or differ greatly from the human disease process.
Methods
Recent advances in bioengineering have led to the emergence of Organ‐on‐Chip (OoC) platforms that aim to recapitulate the human diabetic pancreatic environment. Early T1D‐relevant OoC‐based research focused on the assessment of islet viability. This review turns its attention to the next frontier of vascularised and immune‐competent PoC models, which hold promise for the study of the insulitis of T1D and to predict treatment response to novel therapies.
Results
PoC models can incorporate technologies developed for cancer and non‐diabetes inflammation applications to inform chip design, vascularisation, immune perfusion and pancreatic component incorporation. An established PoC model can then be utilised for a detailed quantitative and qualitative analysis and functional correlation of the immune, vascular and pancreatic components according to an a priori Context of Use (CoU).
Conclusion
The ease of manufacturing, combined with a future possibility of a fully human autologous PoC, could enable high‐throughput screening of T1D tissue for underlying causes of patient heterogeneity that, in turn, could inform personalised treatment approaches, prolonged cell therapy survival and novel preventative measures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering, Faculty of Engineering, Imperial College London, London, UK.
- Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, UK.
- Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
- School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
ORCID-Profile: Maja Witowska, Luigi Margiotta-Casaluci, Periklis Pantazis, Margarita Dominguez-Villar
Förderung
- Medical Research Council
- Leona M. and Harry B. Helmsley Charitable Trust
- Diabetes UK
Zitieren
APA
Witowska, M., Margiotta-Casaluci, L., Pantazis, P., Dominguez-Villar, M., & Salem, V. (2026). Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes. Diabetic Medicine. https://doi.org/10.1111/dme.70495
Vancouver
Witowska M, Margiotta-Casaluci L, Pantazis P, Dominguez-Villar M, Salem V. Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes. Diabetic Medicine. 2026. doi:10.1111/dme.70495
BibTeX
@article{Witowska2026,
author = {Witowska, Maja and Margiotta-Casaluci, Luigi and Pantazis, Periklis and Dominguez-Villar, Margarita and Salem, Victoria},
title = {Immune‐competent organ‐on‐chip methodologies to study type 1 diabetes},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70495}
}
EUVIMED